Abstract
Objective: To evaluate the possible DNA damage in peripheral blood leukocytes of postmenopausal women under different hormone replacement therapies (HRT), comet assay, a standard method for assessing genotoxicity has been used. Method: 46 women were categorized in three groups—Group A: 15 surgical menopausal women who underwent surgery for benign conditions, receiving conjugated equine estrogen, 0.625 mg/day (CEE) for 2.3 ± 1.5 years, Group B: 16 spontaneous menopausal women receiving conjugated equine estrogen, 0.625 mg/day plus medroxyprogesteron acetate, 5 mg/day (CEE + MPA) for 2.4 ± 1.0 years and Group C: 15 spontaneous menopausal women receiving tibolone, 2.5 mg/day for 2.4 ± 1.3 years. Control group consisted of 15 spontaneous menopausal women who never had HRT. Results: Significant differences in terms of DNA damage were observed between Group A and B with controls as mean total comet scores 23.93 ± 5.84, 19.44 ± 6.19 and 10.07 ± 2.40, but no significance ( P > 0.05) were detected between Group C and controls as mean total comet scores 12.07 ± 3.65 and 10.07 ± 2.40, respectively. Conclusion: Reduced DNA damage were observed with tibolone compared to CEE or CEE + MPA therapy. Studies of this approach are needed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
